2؉ /calmodulin-activated protein phosphatase that transduces hypertrophic stimuli to regulate transcriptional control of myocyte transformation. It is not known whether overexpression of MCIP1, a recently described endogenous inhibitor of calcineurin, impacts the hypertrophic response to pathophysiologically relevant pressure overload. Further, the functional consequences of calcineurin inhibition by MCIP1 under conditions of hemodynamic stress are unknown. Transgenic mice expressing a human cDNA encoding hMCIP1 in the myocardium were subjected to thoracic aortic banding. Transgenic mice and wild type littermates tolerated pressure overload equally well. Wild type mice developed left ventricular hypertrophy, but the hypertrophic response in transgenics was significantly blunted. An isoform of MCIP1 transcript was up-regulated by pressure stress, whereas MCIP2 transcript was not. Expression patterns of fetal genes were differentially regulated in banded MCIP1 hearts compared with wild type. Echocardiography performed at 3 weeks and 3 months revealed preservation of both left ventricular size and systolic function in banded MCIP1 mice despite the attenuated hypertrophic response. These data demonstrate attenuation of hypertrophic transformation when calcineurin is inhibited by MCIP1. Further, these data suggest that activation of hypertrophic marker genes may not be directly dependent on calcineurin activity. Finally, they demonstrate that ventricular performance is preserved despite attenuation of compensatory hypertrophy.
Terminally differentiated cardiac myocytes develop hypertrophy in response to stressful stimuli. The resulting increases in left ventricular (LV) 1 wall thickness serve to normalize wall stress and diminish myocardial oxygen consumption. Salutary effects on energy metabolism, however, are counterbalanced by heightened risk of cardiovascular morbidity and mortality (1) . Prominent among these is increased risk of heart failure.
Calcineurin is a Ca 2ϩ /calmodulin-activated cytoplasmic protein phosphatase (PP2B) that transduces hypertrophic stimuli to regulate transcriptional control of myocyte transformation (2) . A number of groups have investigated the importance of calcineurin signaling in models of in vivo hypertrophy (reviewed in Ref. 2) . Although results have been varied, most reports relied on pharmacological inhibition of calcineurin using either cyclosporin A (CsA) or FK-506. Although CsA is a specific inhibitor of calcineurin, CsA has multiple effects on cellular signaling, including altered expression of the cardiac Na ϩ -Ca 2ϩ exchanger (3) and increased concentrations of intracellular Ca 2ϩ (4) . Calcineurin is a ubiquitous protein, and systemic CsA has effects on other, noncardiac organ systems.
MCIP1 (myocyte-enriched calcineurin-interacting protein) is a recently described (5, 6) protein that is preferentially expressed in striated muscle and that directly binds to the catalytic subunit (CnA) of the calcineurin holoenzyme. MCIP1 binding to CnA inhibits activating effects on the nuclear factor of activated T cells (NFAT) or myocyte enhancer factor-2 (MEF2), proteins that transduce calcineurin-generated signals to downstream targets (5) . Expression of the exon 4 isoform of MCIP1 is induced by calcineurin activation (7) . MCIP1 overexpression blunts the hypertrophic response to activated calcineurin in vitro (5) and in the setting of hormonal or exercise stress in vivo (8) . However, no previous studies have determined whether MCIP1 impacts the hypertrophic response to pressure overload in vivo. Further, effects of cardiomyocyte-specific calcineurin suppression on hypertrophic activation of fetal gene expression is unknown.
Recent evidence suggests that hypertrophy is not required for maintenance of systolic performance under all conditions of hemodynamic stress. Mice subjected to surgical banding of the thoracic aorta (TAB) maintain normal systolic performance despite elimination of hypertrophy by calcineurin inhibition with CsA (9) . It is of interest to examine the short and long term necessity of hypertrophy in maintenance of LV systolic performance using a cardiomyocyte-specific means of calcineurin inhibition.
EXPERIMENTAL PROCEDURES
Cardiac-specific Overexpression of MCIP1-Transgenic (TG) mice were engineered to overexpress a human cDNA encoding the calcineurin-binding protein hMCIP1 under the control of the cardiacspecific ␣-myosin heavy chain promoter (8) . Mice were genotyped following sacrifice to ensure blinded surgical intervention and postoperative evaluations.
Pressure Overload Model-Male offspring (6 -8 weeks old) of heterozygous matings were subjected to pressure overload by TAB (10) . Proximal aortic pressures were measured in anesthetized mice as described (9) .
Histology-Hearts were perfusion-fixed in zinc-formalin, embedded in paraffin, sectioned (7 m) between the papillary muscles and the atrioventricular groove, and stained with hematoxylin/eosin or picrosirius red. Short axis cuts of LV were scanned (four to five 50ϫ sections), and the degree of fibrotic change was quantified as red pixels divided by total pixels, as determined by image analysis software.
RNA Expression-Total RNA from TAB and sham-operated hearts (2-g dot blots, 20-g Northern blots) was transferred to nylon membranes and hybridized with 32 P-labeled cDNA fragments or antisense oligonucleotides. Signal intensity was detected on a Storm PhosphorImager (Molecular Dynamics) and quantified using IMAGEQUANT (version 1.2).
Echocardiography-Transthoracic echocardiograms were recorded in conscious sedated mice as described (9) . LV internal diameters and wall thicknesses were measured (at least three cardiac cycles) at end systole and end diastole from two-dimensionally targeted M-mode cross-sectional views at the level of the chordae tendineae. Heart rate was determined from mitral inflow Doppler envelopes.
Statistical Methods-Averaged data are reported as mean Ϯ S.E. Statistical significance was analyzed using a Student's unpaired t test or one-way analysis of variance followed by Bonferroni's method for post hoc pair-wise multiple comparisons.
RESULTS
As reported previously (8), MCIP1 transgenic mice developed normally and did not exhibit overt signs of circulatory compromise. Pressure overload, induced by surgical banding of the thoracic aorta, was tolerated equally well in transgenic mice and in wild type littermates. There were no detectable clinical differences (lethargy, tachypnea, impaired mobility, edema), and the mice did not exhibit signs of cardiovascular compromise (effusions, ascites, hepatic congestion). Body mass continued to increase normally in both groups (data not shown). Perioperative (Ͻ5%) and 3-week mortalities (Ͻ10%) were similar.
At 3 weeks, a point where the hypertrophic response is near steady state (9), hearts were dissected and weighed, and mice were tested for the presence of the MCIP1 transgene. Integrity of aortic banding was confirmed by inspection of the surgical constriction and by visualization of marked differences in caliber of the right and left carotid arteries. Heart mass in wild type (WT) mice increased 65% from 115 Ϯ 2 to 190 Ϯ 10 mg (p Ͻ 0.05) (Fig. 1) . Heart mass normalized to tibia length (HW/T) increased 63% (p Ͻ 0.05) from 6.8 Ϯ 0.1 to 11.1 Ϯ 0.6 mg/mm (Fig. 1B) . Heart mass normalized to body mass (HW/ BW) increased 70% (p Ͻ 0.05) from 4.6 Ϯ 0.1 (n ϭ 5) to 7.8 Ϯ 0.4 mg/g (n ϭ 23). In both WT and transgenic animals, heart mass was similar in sham-operated and unoperated controls.
In contrast, increases in heart mass in MCIP1 transgenic mice were significantly attenuated, increasing from 105 Ϯ 4 (n ϭ 7) to 158 Ϯ 8 mg (n ϭ 23). HW/T increased 46% from 6.3 Ϯ 0.2 to 9.2 Ϯ 0.4 mg/mm (p Ͻ 0.05 versus unoperated MCIP1; p Ͻ 0.05 versus WT TAB) (Fig. 1B) . HW/BW increased 40% from 4.8 Ϯ 0.1 to 6.7 Ϯ 0.3 mg/g (p Ͻ 0.05 versus unoperated MCIP1; p Ͻ 0.05 versus WT TAB). Thus, MCIP1 overexpression was associated with a significant reduction in pressure overload-induced increases in HW/T (decreased 27%, p Ͻ 0.01) and HW/BW (decreased 43%, p Ͻ 0.01). There were no significant differences in either HW/T or HW/BW in unoperated MCIP1 transgenic mice and WT littermate controls.
Whereas pharmacologic inhibition of calcineurin blunts the hypertrophic response to pressure stress, long term (Ն2-3 months) cyclosporin treatment is not well tolerated in mice. 2 To determine the longevity of the attenuated hypertrophic response stemming from calcineurin suppression, a group of mice was followed out to 3 months. Whereas heart mass at 3 months was significantly increased (p Ͻ 0.01) in both WT and MCIP1 mice, the hypertrophic response in MCIP1 mice (HW/T 7.9 Ϯ 0.6 mg/mm, n ϭ 5) was attenuated relative to WT (HW/T 10.1 Ϯ 0.3 mg/mm, n ϭ 5) to an extent similar to that observed at 3 weeks (Fig. 1B) .
Short axis sections through the heart at the level of the papillary muscles ( Fig. 2A) revealed thickening of the left ventricular wall in WT hearts following TAB at 3 weeks, whereas wall thickening was attenuated in hearts from banded MCIP1 mice. Quantification of fibrotic change revealed a trend (p ϭ NS) toward decreased perivascular and subendocardial fibrosis (Fig. 2B ) in banded MCIP1 hearts (2.5 Ϯ 0.8%, n ϭ 4) compared with banded WT (3.8 Ϯ 0.8%, n ϭ 9).
MCIP1 Up-regulation by Pressure Stress-The human MCIP1 gene expresses four variant mRNAs leading to unique 5Ј termini of the expressed transcripts (11) . In mouse, expression of the exon 4 isoform is regulated by calcineurin activity (7) . To determine whether MCIP1 expression increases under conditions of pressure-overload stress, we measured transcript levels of MCIP1 (exon 1 and exon 4 variants) and MCIP2 by Northern blotting (Fig. 3) and normalized the results to glyceraldehyde-3-phosphate dehydrogenase transcript levels. MCIP2 transcript levels were not increased by TAB in both WT (average -fold change 1.5, n ϭ 5, p ϭ NS) and TG (average -fold change 1.3, n ϭ 3, p ϭ NS) animals. A similar insensitivity to pressure stress was observed for the exon 1 variant of MCIP1 (data not shown). In contrast, steady-state levels of the exon 4 isoform of the MCIP1 transcript were significantly increased by TAB in both WT (average -fold change 16, n ϭ 5, p Ͻ 0.05) and TG animals (average -fold change 6, n ϭ 3, p Ͻ 0.05). The degree of exon 4 up-regulation varied over wide ranges in both WT (3-47-fold) and TG (2-13-fold) mice. Preliminary data suggest that the magnitude of exon 4 expression was proportional to the degree of myocardial hypertrophy elicited by the pressure stress.
Hypertrophic Markers-Hypertrophic transformation involves myocyte dedifferentiation and activation of a fetal gene program. However, the role of calcineurin signaling therein is not known. Analysis of total heart RNA revealed elevation of atrial natriuretic factor (ANF) and ␣-skeletal actin transcript levels in both WT and MCIP1 TAB hearts (Fig. 4A) . Remarkably, ANF expression was more robust in the MCIP1 TAB hearts compared with WT TAB. Within each genotype, over a wide range of hypertrophy, there was a linear relationship between ANF expression and LV mass (Fig. 4B) , although the slope of this relationship was steeper in the MCIP1 TAB animals compared with WT TAB. Expression of brain natriuretic peptide was similar to that of ANF, i.e. elevated in MCIP1 TAB hearts relative to WT TAB (Fig. 4C) . ␤-myosin heavy chain transcript levels were modestly increased to similar extents in both genotypes (Fig. 4C) . In contrast, the expression of ␣-skeletal actin was reduced in MCIP1 TAB hearts compared with WT TAB hearts (Fig. 4, A and C) .
In Vivo Function-Previous work from our laboratory has shown that systolic performance can be preserved in this model at 3 weeks despite abolition of the structural hypertrophic response (9). To explore this using an endogenous negative regulator of calcineurin, we evaluated LV size and function by echocardiography. Under these recording conditions, there were no significant differences in heart rate (MCIP1 TAB, 600 Ϯ 19 bpm, n ϭ 5; WT TAB, 625 Ϯ 30 bpm, n ϭ 6; unoperated MCIP1, 616 Ϯ 20 bpm, n ϭ 6; unoperated WT, 610 Ϯ 29 bpm, n ϭ 7).
Proximal aortic pressures were similar (p ϭ NS) in transgenic (171/81 Ϯ 17/5, n ϭ 4) and WT (166/69 Ϯ 12/5, n ϭ 4) mice, suggesting similarity in the cardiac responses to the surgical stenosis. Echocardiographically determined LV wall thicknesses increased significantly in banded WT (34%, p Ͻ 0.01) and banded TG (21%, p Ͻ 0.05) mice, but the increase was significantly (p Ͻ 0.05) blunted in MCIP1 mice (Table I) . Systolic performance, measured as percent fractional shortening (FS) in M-mode tracings (Fig. 5A) , was similar in unoperated MCIP1 transgenic mice (52 Ϯ 5, n ϭ 9) compared with WT littermates (56 Ϯ 8, n ϭ 11) (p ϭ NS) . Echocardiograms recorded 3 weeks post-banding revealed preservation of systolic function in both hypertrophied WT mice (FS ϭ 57 Ϯ 10, n ϭ 6) and in MCIP1 transgenics (FS ϭ 56 Ϯ 8, n ϭ 5), despite the blunted hypertrophic response in the latter group (Fig. 5B) . Measurements of left ventricular end diastolic dimension were similar (p ϭ NS) in all four groups (WT, 2.0 Ϯ 0.2 mm, n ϭ 11; MCIP1, 2.0 Ϯ 0.1, n ϭ 9; WT TAB, 1.7 Ϯ 0.4, n ϭ 6; MCIP1 TAB, 1.8 Ϯ 0.1, n ϭ 5), ruling out significant ventricular dilatation as a contributor to cardiac output.
To test the longevity of preserved systolic performance, a group of MCIP1 animals (n ϭ 9) was followed out to 3 months post-TAB. There were no clinical signs of circulatory compromise, and mortality was not increased at 3 months. Necropsy analysis failed to reveal evidence of heart failure. Echocardiograms confirmed the preservation of systolic performance with percent fractional shortening measured at 51 Ϯ 9 (n ϭ 9) (Fig.   5B ) and heart rate measured at 627 Ϯ 18 bpm. The LV cavity was not dilated (end diastolic dimension 2.4 Ϯ 0.3 mm).
DISCUSSION
Involvement of the calcineurin-NFAT/MEF2 pathway in hypertrophic signaling has been demonstrated using a variety of approaches that include both cell culture and intact animal models (reviewed in Ref. 2) . Controversy over the importance of calcineurin signaling in medically relevant forms of hypertrophy persists, but the concept recently has gained increasing acceptance (12, 13) . By inhibiting calcineurin selectively within the myocardium, we demonstrate that inhibition of hypertrophy is cell autonomous and not because of noncardiac (e.g. neural) effects of calcineurin suppression. Similar results were recently reported using other transgenic approaches (14, 15) .
MCIP1 is present at high levels in normal myocardium, and its expression is regulated by calcineurin activity (7) . MCIP1 overexpression inhibited the hypertrophic response to aortic banding (this study) or hormonal stress (8) , and clinical and echocardiographic measures of cardiac performance under basal conditions were preserved. We report that the exon 4 variant of MCIP1 is up-regulated by TAB, and preliminary evidence suggests that the extent of exon 4 up-regulation is proportional to the degree of myocardial hypertrophy. Together, these data suggest that MCIP1 may be an endogenous regulator of hypertrophic signaling in the heart that does not prevent normal heart growth and development. Thus, MCIP1 up-regulation may be an attractive target for therapeutic intervention in patients with heart disease.
Fetal Gene Expression-Increases in ANF expression were greater in the MCIP1 TAB hearts compared with WT. This unexpected finding suggests that activation of ANF expression is not directly dependent on calcineurin activity but rather occurs prior to or in parallel with calcineurin signaling. It is n ϭ 11 n ϭ 9 n ϭ 9 Diastole (14) expressed calcineurin inhibitory domains from two different proteins and observed significant attenuation of hypertrophic marker changes. At this point, we do not know why fetal gene expression is different in the MCIP1 TAB mice compared with these other models, even though attenuation of hypertrophy was similar. It is possible that differential inhibition of other calmodulin-dependent enzymes such as CaMKIV (16) may occur in these models. We speculate that the endogenous calcineurin inhibitory protein MCIP1 may exhibit some degree of specificity, inhibiting dephosphorylation of a narrower range of targets. More experiments are required to ascertain the relative contribution of calcineurin and other hypertrophic signaling pathways in the induction of the fetal gene program.
Functional Consequences of Calcineurin Inhibition by MCIP1-We observed preservation of circulatory performance in MCIP1 mice at 3 weeks and at 3 months post-banding. The finding that ventricular decompensation does not occur in the setting of Ϸ50 mm Hg systolic pressure overload despite attenuation of the hypertrophic response is supported by four independent lines of evidence. First, there was no clinical or actuarial evidence of heart failure in banded transgenic mice. Second, post-mortem gross anatomy demonstrated no signs of cardiac dilatation or evidence of heart failure (e.g. effusions, ascites, edema). Third, we observed a trend toward diminished fibrosis in 3-week banded MCIP1 hearts. Finally, echocardiography consistently demonstrated maintenance of normal systolic size and function in banded transgenic mice.
Hypertrophy occurring as a consequence of pressure overload is termed "compensatory" on the premise that it facilitates ejection performance by normalizing systolic and diastolic wall stress. We and others have shown recently that cardiac hypertrophy is not required in the short term to maintain systolic function in the face of pressure overload (9, (17) (18) (19) (20) (21) . Maintenance of cardiac output in the face of increased afterload but without change in end diastolic or end systolic volumes (homeometric autoregulation) was first described in 1912 and has been reported subsequently in a variety of working heart models (9) . Although the molecular mechanism underlying homeometric autoregulation remains unknown, the findings reported here are consistent with a sustained Anrep effect.
